Displaying publications 1 - 20 of 51 in total

Abstract:
Sort:
  1. MENON KA
    Med J Malaysia, 1963 Dec;18:91-4.
    PMID: 14117287
    Matched MeSH terms: Prostatic Hyperplasia*
  2. Yeoh N, Inbasegaran K
    Med J Malaysia, 1989 Jun;44(2):129-33.
    PMID: 2483248
    Transurethral Resection of the Prostate (TURP) is now the preferred method for dealing with the obstructing prostate. This procedure was reintroduced to the Penang General Hospital in August 1985. Over the next one and a half years, 100 TURP were performed by the author (NYTL). This paper reviews this initial experience. Of the patients, 17.7% required blood transfusion of one unit each. The mean post operative stay was 4.8 days. There were no immediate deaths. This experience confirms the acceptable results of TURP in the treatment of patients with benign prostatic hypertrophy in the Malaysian context.
    Matched MeSH terms: Prostatic Hyperplasia/surgery*
  3. Khalid BA, Nurshireen A, Rashidah M, Zainal BY, Roslan BA, Mahamooth Z
    Med J Malaysia, 1990 Jun;45(2):148-53.
    PMID: 1725553
    One hundred and six prostatic tissue samples obtained from transurethral resection were analysed for androgen and estrogen receptors. In 62 of these, progesterone and glucocorticoid receptors were also assayed. Steroid receptors were assayed using single saturation dose 3H-labelled ligand assays. Ninety percent of the 97 prostatic hyperplasia tissues and six of the nine prostatic carcinoma tissues were positive for androgen receptors. Estrogen receptors were only present in 19% and 33% respectively. Progesterone receptors were present in 70% of the tissues, but glucocorticoid receptors were present in only 16% of prostatic hyperplasia and none in prostatic carcinoma.
    Matched MeSH terms: Prostatic Hyperplasia/metabolism*
  4. Liong ML, Suzuki T, Yamanaka H, Kurokawa K, Daikuzono N, Nakazato M
    J Clin Laser Med Surg, 1994 Apr;12(2):85-92.
    PMID: 10151050
    Prostalase¿ has a probe that emits a laser beam at 360 degrees . Targeted obstructive prostatic adenoma tissue was heated to above the cytotoxic threshold temperature of 45 degrees C. After successful canine prostate study, from September 1992 to April 1993, 45 patients were treated. This paper reports the 9 months results of this initial cohort of patients. Prostatic and periprostatic temperature mapping showed the mean temperature within the adenoma zone was 49 degrees C, while the periprostatic tissue remained within the safety level of less than 42.5 degrees C. The mean prostate volume reductions at 3, 6, and 9 months were 36, 33, and 38%, respectively. Those patients whose surgery was unsuccessful had prostatic tissue removed by TURP at 2 to 3 months. This tissue revealed a definite zone of coagulative necrosis. For the clinical assessment, patients were divided into urine retention (UR) and nonretention (NR) subgroups. At 9 months, 20 of the 32 UR subgroup and 10 of the 13 NR subgroup patients were available for assessment. Due to poor response or complications, 6 of the 26 UR patients (23%) required ancillary treatment. Hence, 20 of the 26 cases (77%) remained catheter free and their mean maximum uroflow +/- SE was 9.6 +/- 0.7 ml/sec. Based on a Siroky normogram only 7 of these 26 patients (27%) became unobstructed. Two of the 12 NR subgroup patients (17%) required ancillary treatment. The mean maximum uroflow +/- SE was 10.7 +/- 1.2 ml/sec.(ABSTRACT TRUNCATED AT 250 WORDS)
    Matched MeSH terms: Prostatic Hyperplasia/therapy*
  5. Ng PEP
    Family Physician, 1995;7:12-15.
    Matched MeSH terms: Prostatic Hyperplasia
  6. Tan HM, Lei CCM
    Family Physician, 1995;7:16-21.
    Medical therapy is effective in patients with mild to moderate symptoms of benign prostatic hyperplasia. Selective alpha-1 blockers (e.g. terazosin) and 5 alpha reductase inhibitors (e.g. finasteride) are the main drugs used. Alpha blockers reduce the dynamic component of obstruction while the later reduces the size of the prostate.
    Matched MeSH terms: Prostatic Hyperplasia
  7. Yap HW
    Family Physician, 1995;7:9-11.
    Matched MeSH terms: Prostatic Hyperplasia
  8. Lim CS
    Family Physician, 1995;7:6-8.
    Matched MeSH terms: Prostatic Hyperplasia
  9. Lei CCM
    Family Physician, 1995;7:3-5.
    Matched MeSH terms: Prostatic Hyperplasia
  10. Lei CCM
    Family Physician, 1995;7:22-23.
    Matched MeSH terms: Prostatic Hyperplasia
  11. Quek KF, Low WY, Razack AH, Loh CS
    BJU Int, 2000 Oct;86(6):630-3.
    PMID: 11069367
    OBJECTIVE: To assess and evaluate the level of depression, anxiety and psychiatric status in patients with lower urinary tract symptoms (LUTS) before and after treatment by surgery or drugs.

    PATIENTS AND METHODS: The study included 123 patients (mean age 64.6 years, SD 7. 95) with LUTS who were treated medically (with alpha-blockers, i.e. terazosin, prazosin, doxazosin and alfuzosin), and 52 patients (mean age 69.6 years, SD 7.94) with LUTS and confirmed to have benign prostatic hyperplasia (BPH) who underwent transurethral resection of the prostate (TURP). Both groups were assessed at baseline and 3 months after treatment using standardized questionnaires (the Beck Depression Inventory, the State-Trait Anxiety Inventory and the General Health Questionnaire-12).

    RESULTS: Patients before TURP were significantly more depressed, worried and psychiatrically morbid than were those before medical treatment. Three months after medical and surgical treatment, there was significantly less depression, anxiety and psychiatric morbidity in the TURP than in the medication group.

    CONCLUSIONS: TURP is a better treatment than medication for minimising anxiety, depression and psychiatric morbidity after treatment in patients with LUTS, but causes greater psychological stress before treatment.

    Matched MeSH terms: Prostatic Hyperplasia/psychology*
  12. Saw S, Aw TC
    Pathology, 2000 Nov;32(4):245-9.
    PMID: 11186419
    Cancer of the prostate is the sixth most frequently found cancer in Singapore. Prostate-specific antigen (PSA) is the most clinically useful tumour marker available today for the diagnosis and management of prostate cancer. To enhance the value of PSA as a screening test we developed age-specific intervals for our ethnic population. The measurement of free PSA was included in the study to calculate the free:total ratio which enhances the differential diagnosis of prostate cancer from benign prostatic hyperplasia or prostatitis. The total PSA upper limits of 10-year intervals, beginning at 30-years-old, were 1.4, 1.7, 2.3, 4.0, 6.3 and 6.6 microg/l. Free PSA cut-off limits were 0.4, 0.5, 0.5, 1.0, 1.5 and 1.6 microg/l. The free:total ratio of PSA was not age dependent. Abbott AxSym standardised their calibration material for both free and total PSA assays with the Stanford 90:10 reference material. This laboratory has implemented these age-specific reference intervals and are currently following up their pick-up rate in the detection of prostate cancer.
    Matched MeSH terms: Prostatic Hyperplasia/blood*; Prostatic Hyperplasia/epidemiology
  13. Quek KF, Low WY, Razack AH, Loh CS, Chua CB
    Asia Pac J Public Health, 2000;12(2):107-17.
    PMID: 11836919 DOI: 10.1177/101053950001200210
    This study aims to assess the impact of medical and surgical treatment on treating lower urinary tract symptoms (LUTS) on pain, prostatic symptoms, disease-specific quality of life and health-related quality of life. Patients scheduled for medical (alpha-blockers) and surgical treatment (transurethral resection of the prostate, TURP) were recruited in the study. The patients were assessed using the Visual Analogue Scale (VAS), Present Pain Intensity (PPI), International Prostate Symptom Score (I-PSS) and Health-Related Quality of Life (HRQOL) at 3-month, 6-month and 12-month (baseline). Before treatment, most of the patients with LUTS had severe pain, LUTS and deterioration of health-related quality of life. Following treatment, both medical and surgical treatment improved their pain, LUTS and health-related quality of life. Both treatments are effective in relieving the symptoms of pain, LUTS and health-related quality of life.
    Matched MeSH terms: Prostatic Hyperplasia/complications*; Prostatic Hyperplasia/drug therapy; Prostatic Hyperplasia/surgery
  14. Teh GC, Sahabudin RM, Lim TC, Chong WL, Woo S, Mohan M, et al.
    Med J Malaysia, 2001 Jun;56(2):186-95.
    PMID: 11771079
    Objective: To study the prevalence of symptomatic BPE among Malaysian men age 50 and above attending prostate health awareness campaign and to identify differences in prevalence between different ethnic groups residing within metropolitan Kuala Lumpur.
    Materials and Methods: Demographic data and the completed International Prostate Symptom Score (IPSS), maximal uroflow rate (Qmax) and prostate size of volunteers, aged 50 and above, who attended the prostate health awareness campaign were analyzed. Subjects with known prostate diseases or prostate surgery, bladder disorders and neurological disorders were excluded.
    Results: 2086 volunteers attended the campaign. 575 men fulfilled the inclusion criteria and their demographic data, IPSS; peak flow rate and prostate volume were analysed. Overall, 18.9% and 39.6% of the men were severely and moderately symptomatic, respectively. The prevalence of moderate to severe lower urinary tract symptoms (LUTS) in Malays, Chinese and Indians were 70%, 59% and 50% respectively (p=0.004). The commonest bothersome symptoms were nocturia (56%), frequency (50.4%) and sense of incomplete voiding (43.5%). The mean peak flow rate of the subjects was 15.4ml/s. 20.9% and 55.2% of the subjects had peak flow less than 10ml/sec and 15ml/sec respectively. The mean prostate size was 25.1cc. There is no significant difference in term of maximal flow rate and prostate size among Malays, Chinese and Indians in Malaysia. A good correlation was found between the total symptom score and the single disease-specific quality of life question (r=0.69, p<0.001). The correlation between IPSS and peak flow rate (r=-0.22, p<0.001) and prostate volume (r=0.11, p=0.009) was weak. There was no correlation between IPSS and age (r=0.06, p=0.17). The prevalence of symptomatic benign prostate enlargement (BPE) was 39.3%. The prevalence increased 8% per decade from 41.7% for men aged 50 to 59 to 65.4% for men aged 70 or more. There is no significant difference in prevalence of symptomatic BPE among the three ethnic groups. The prevalence of BPO was 15.8%.
    Conclusion: The correlation between symptom score, maximal flow rate and prostate size was poor and one cannot predict the value of one parameter by knowing one or more of the other parameters. There is a high prevalence of LUTS suggestive of benign prostatic obstruction in the apparently healthy Malaysian aged 50 and above attending the prostate health awareness campaign.

    Matched MeSH terms: Prostatic Hyperplasia/diagnosis*; Prostatic Hyperplasia/epidemiology*
  15. Quek KF, Low WY, Razack AH, Loh CS
    BJU Int, 2001 Jul;88(1):21-5.
    PMID: 11446839
    OBJECTIVE: To validate the English version of the International Prostate Symptom Score (IPSS) in patients with and without urinary symptoms in a Malaysian population.

    PATIENTS AND METHODS: Validity and reliability were assessed in patients with lower urinary tract symptoms (LUTS) and in patients with no LUTS. Reliability was evaluated using the test-retest method and internal consistency using Cronbach's alpha. Sensitivity to change was expressed as the effect size in the score before and after intervention in additional patients with LUTS who underwent transurethral resection of the prostate (TURP).

    RESULTS: Internal consistency was excellent; there was a high degree of internal consistency for each of the seven domains and for the total score (Cronbach's alpha > or = 0.60 and > or = 0.79, respectively) in the populations studied. The test-retest correlation coefficient for the seven domain scores was highly significant. The intra-class correlation coefficient was high (> or = 0.59). There was a high level of sensitivity and specificity for the effects of treatment, with a very significant change between the seven scores domains in the treated group but not in the control group.

    CONCLUSIONS: The IPSS is suitable, reliable, valid and sensitive to clinical change in the Malaysian population.

    Matched MeSH terms: Prostatic Hyperplasia/diagnosis*
  16. Quek KF, Low WY, Razack AH, Loh CS
    Psychiatry Clin Neurosci, 2001 Oct;55(5):509-13.
    PMID: 11555347 DOI: 10.1046/j.1440-1819.2001.00897.x
    This present study was undertaken to validate the English version of the General Health Questionnaire (GHQ-12) in urological patients. Validity and reliability were studied in patients with lower urinary tract symptoms (LUTS) and patients without LUTS. Reliability was evaluated using the test-retest method and internal consistency was assessed using Cronbach's alpha. Sensitivity to change was expressed as the effect size in the pre-intervention versus post-intervention score in additional patients with benign prostatic hyperplasia (BPH) who underwent transurethral resection of the prostate (TURP). Internal consistency was excellent. A high degree of internal consistency was observed for each of the 12 items with Cronbach's alpha value of 0.37-0.79, while total scores was 0.79 in the population study. Test-retest correlation coefficient for the 12 items score were highly significant. Intraclass correlation coefficient was high (0.35-0.79). It showed a high degree of sensitivity and specificity to the effects of treatment. A high degree of significant level between baseline and post-treatment scores were observed across all 12 items in the treatment cohort but not in the control group. The GHQ-12 is suitable, reliable, valid and sensitive to clinical change in urological disorders.
    Matched MeSH terms: Prostatic Hyperplasia/psychology*; Prostatic Hyperplasia/surgery
  17. Quek KF, Low WY, Razack AH, Sin Loh C, Chua CB
    J Urol, 2002 Mar;167(3):1359-62.
    PMID: 11832732
    PURPOSE: We validated the Malay version of the International Prostate Symptom Score in patients with and without urinary symptoms in the Malaysian population.

    MATERIALS AND METHODS: Validity and reliability were studied in patients with and without lower urinary tract symptoms. Reliability was evaluated using the test-retest method and internal consistency was assessed by Cronbach's alpha. Sensitivity to change was expressed as the effect size in the pre-intervention versus post-intervention score in additional patients with lower urinary tract symptoms who underwent transurethral prostate resection.

    RESULTS: Internal consistency was excellent. A high degree of internal consistency was observed for each of the 7 items and for the total score (Cronbach's alpha 0.53 and greater, and 0.68, respectively). The test-retest correlation coefficients of the 7 items were highly significant. The intraclass correlation coefficient was high at 0.51 and greater. There was a high degree of sensitivity and specificity to the effects of treatment. Significant change from baseline to posttreatment scores was observed in all 8 items in the treated but not in the control group.

    CONCLUSIONS: The Malay International Prostate Symptom Score is a suitable, reliable, valid instrument that is sensitive to clinical change in the Malaysian population.

    Matched MeSH terms: Prostatic Hyperplasia/diagnosis*; Prostatic Hyperplasia/ethnology*
  18. Loh SY, Chin CM
    BJU Int, 2002 Apr;89(6):531-3.
    PMID: 11942958
    OBJECTIVE: To evaluate, in a prospective study, the demographic profile of patients with benign prostate enlargement who presented in acute urinary retention (AUR).

    PATIENTS AND METHODS: The study comprised all patients admitted for transurethral resection of the prostate and categorised into two groups, i.e. those presenting in AUR or electively. The factors evaluated included the length of hospitalization, the patients' occupation, their duration of symptoms and reasons for not seeking treatment.

    RESULTS: There was no significant difference in the mean age and occupational status of the two groups but those in AUR had more complications and a longer hospital stay after surgery; 60% of these men had had their urinary symptoms for > 1 year. When asked why they did not seek treatment earlier, 35% reported fear of surgery, while 41% thought that their symptoms were a normal part of ageing.

    CONCLUSION: There is a need to raise the level of public awareness of benign prostatic enlargement because those who present with AUR incur excess morbidity and longer hospitalization that could otherwise be avoided through earlier treatment and elective surgery.

    Matched MeSH terms: Prostatic Hyperplasia/complications; Prostatic Hyperplasia/surgery*
  19. Quek KF, Loh CS, Low WY, Razack AH, Chua CB
    Singapore Med J, 2002 Aug;43(8):391-8.
    PMID: 12507023
    This study examined the effects of treatment of lower urinary tract symptoms (LUTS) on the health-related quality of life (physical/functional, mental, social and global aspect), pain and prostatic symptoms.
    Matched MeSH terms: Prostatic Hyperplasia/drug therapy; Prostatic Hyperplasia/physiopathology*; Prostatic Hyperplasia/surgery
  20. Quek KF, Low WY, Razack AH, Chua CB, Loh CS
    J Sex Marital Ther, 2002 Oct-Dec;28(5):423-6.
    PMID: 12378843
    The purpose of this study is to validate the English version of the Golombok-Rust Inventory of Marital State (GRIMS) in a Malaysian population. Using the test-retest method and Cronbach's alpha, we assessed reliability and internal consistency. Sensitivity to change was expressed as the effect size. Internal consistency was excellent (Cronbach's alpha value = 0.59 to 0.91) Test-retest correlation coefficient and intraclass correlation coefficient were highly significant in majority items (ICC = 0.62 and above), and there was a high degree of sensitivity and specificity. The GRIMS is suitable, reliable, valid, and sensitive to clinical change in a Malaysian population.
    Matched MeSH terms: Prostatic Hyperplasia/complications*; Prostatic Hyperplasia/psychology
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links